source
- Regeneron's POTS antibody shows heart-rate reduction in Phase 2, paving way for Phase 3 trialRegeneron reported results from its Phase 2 Pinnacle trial of a monoclonal antibody targeting postural orthostatic tachycardia syndrome (POTS), a disorder with no approved therapies. The trial enr…
- Windward Bio raises $175M in IPO, boosting 2026 biotech debut count to 35Windward Bio completed an initial public offering that raised about $175 million, selling roughly 10.3 million shares at $17 each on the Nasdaq. The proceeds are earmarked to advance its lead antib…